Rapport Therapeutics (RAPP) said Friday that data from a proof-of-concept study of RAP-219 showed a link between a seizure biomarker and clinical seizures.
The data showed that a 30% reduction in long episode frequency was associated with a decrease of at least 50% in clinical seizures, regardless of the antiseizure medication used, according to the company.
This sets the benchmark for evaluating the potential efficacy of antiseizure treatments, including RAP-219, the company said.
Price: 20.17, Change: -0.11, Percent Change: -0.52
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.